These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

349 related articles for article (PubMed ID: 30470647)

  • 1. Risk Stratification Tools and Prognostic Models in Non-muscle-invasive Bladder Cancer: A Critical Assessment from the European Association of Urology Non-muscle-invasive Bladder Cancer Guidelines Panel.
    Soukup V; Čapoun O; Cohen D; Hernández V; Burger M; Compérat E; Gontero P; Lam T; Mostafid AH; Palou J; van Rhijn BWG; Rouprêt M; Shariat SF; Sylvester R; Yuan Y; Zigeuner R; Babjuk M
    Eur Urol Focus; 2020 May; 6(3):479-489. PubMed ID: 30470647
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Validation of EORTC, CUETO, and EAU risk stratification in prediction of recurrence, progression, and death of patients with initially non-muscle-invasive bladder cancer (NMIBC): A cohort analysis.
    Jobczyk M; Stawiski K; Fendler W; Różański W
    Cancer Med; 2020 Jun; 9(11):4014-4025. PubMed ID: 32216043
    [TBL] [Abstract][Full Text] [Related]  

  • 3. EAU Guidelines on Non-Muscle-invasive Urothelial Carcinoma of the Bladder: Update 2016.
    Babjuk M; Böhle A; Burger M; Capoun O; Cohen D; Compérat EM; Hernández V; Kaasinen E; Palou J; Rouprêt M; van Rhijn BWG; Shariat SF; Soukup V; Sylvester RJ; Zigeuner R
    Eur Urol; 2017 Mar; 71(3):447-461. PubMed ID: 27324428
    [TBL] [Abstract][Full Text] [Related]  

  • 4. European Association of Urology Guidelines on Non-muscle-invasive Bladder Cancer (TaT1 and Carcinoma In Situ) - 2019 Update.
    Babjuk M; Burger M; Compérat EM; Gontero P; Mostafid AH; Palou J; van Rhijn BWG; Rouprêt M; Shariat SF; Sylvester R; Zigeuner R; Capoun O; Cohen D; Escrig JLD; Hernández V; Peyronnet B; Seisen T; Soukup V
    Eur Urol; 2019 Nov; 76(5):639-657. PubMed ID: 31443960
    [TBL] [Abstract][Full Text] [Related]  

  • 5. EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder: update 2013.
    Babjuk M; Burger M; Zigeuner R; Shariat SF; van Rhijn BW; Compérat E; Sylvester RJ; Kaasinen E; Böhle A; Palou Redorta J; Rouprêt M;
    Eur Urol; 2013 Oct; 64(4):639-53. PubMed ID: 23827737
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Updated European Association of Urology (EAU) Prognostic Factor Risk Groups Overestimate the Risk of Progression in Patients with Non-muscle-invasive Bladder Cancer Treated with Bacillus Calmette-Guérin.
    Lobo N; Hensley PJ; Bree KK; Nogueras-Gonzalez GM; Navai N; Dinney CP; Sylvester RJ; Kamat AM
    Eur Urol Oncol; 2022 Feb; 5(1):84-91. PubMed ID: 34920986
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Deep Learning-based Recalibration of the CUETO and EORTC Prediction Tools for Recurrence and Progression of Non-muscle-invasive Bladder Cancer.
    Jobczyk M; Stawiski K; Kaszkowiak M; Rajwa P; Różański W; Soria F; Shariat SF; Fendler W
    Eur Urol Oncol; 2022 Feb; 5(1):109-112. PubMed ID: 34092528
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Utility of the EORTC risk tables and CUETO scoring model for predicting recurrence and progression in non-muscle-invasive bladder cancer patients treated with routine second transurethral resection.
    Zhang G; Steinbach D; Grimm MO; Horstmann M
    World J Urol; 2019 Dec; 37(12):2699-2705. PubMed ID: 30911812
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Accuracy of the EORTC risk tables and of the CUETO scoring model to predict outcomes in non-muscle-invasive urothelial carcinoma of the bladder.
    Xylinas E; Kent M; Kluth L; Pycha A; Comploj E; Svatek RS; Lotan Y; Trinh QD; Karakiewicz PI; Holmang S; Scherr DS; Zerbib M; Vickers AJ; Shariat SF
    Br J Cancer; 2013 Sep; 109(6):1460-6. PubMed ID: 23982601
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Predicting Nonmuscle Invasive Bladder Cancer Recurrence and Progression in a United States Population.
    Ravvaz K; Walz ME; Weissert JA; Downs TM
    J Urol; 2017 Oct; 198(4):824-831. PubMed ID: 28433642
    [TBL] [Abstract][Full Text] [Related]  

  • 11. European Association of Urology Guidelines on Non-muscle-invasive Bladder Cancer (Ta, T1, and Carcinoma in Situ).
    Babjuk M; Burger M; Capoun O; Cohen D; Compérat EM; Dominguez Escrig JL; Gontero P; Liedberg F; Masson-Lecomte A; Mostafid AH; Palou J; van Rhijn BWG; Rouprêt M; Shariat SF; Seisen T; Soukup V; Sylvester RJ
    Eur Urol; 2022 Jan; 81(1):75-94. PubMed ID: 34511303
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of expected treatment outcomes, obtained using risk models and international guidelines, with observed treatment outcomes in a Dutch cohort of patients with non-muscle-invasive bladder cancer treated with intravesical chemotherapy.
    Lammers RJ; Palou J; Witjes WP; Janzing-Pastors MH; Caris CT; Witjes JA
    BJU Int; 2014 Aug; 114(2):193-201. PubMed ID: 24304638
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Non-muscle invasive bladder cancer risk stratification.
    Isharwal S; Konety B
    Indian J Urol; 2015; 31(4):289-96. PubMed ID: 26604439
    [TBL] [Abstract][Full Text] [Related]  

  • 14. External validation of European Organization for Research and Treatment of Cancer and Spanish Urological Club for Oncological Treatment scoring models to predict recurrence and progression in Japanese patients with non-muscle invasive bladder cancer treated with bacillus Calmette-Guérin.
    Kohjimoto Y; Kusumoto H; Nishizawa S; Kikkawa K; Kodama Y; Ko M; Matsumura N; Hara I
    Int J Urol; 2014 Dec; 21(12):1201-7. PubMed ID: 25074295
    [TBL] [Abstract][Full Text] [Related]  

  • 15. EORTC Nomograms and Risk Groups for Predicting Recurrence, Progression, and Disease-specific and Overall Survival in Non-Muscle-invasive Stage Ta-T1 Urothelial Bladder Cancer Patients Treated with 1-3 Years of Maintenance Bacillus Calmette-Guérin.
    Cambier S; Sylvester RJ; Collette L; Gontero P; Brausi MA; van Andel G; Kirkels WJ; Silva FC; Oosterlinck W; Prescott S; Kirkali Z; Powell PH; de Reijke TM; Turkeri L; Collette S; Oddens J
    Eur Urol; 2016 Jan; 69(1):60-9. PubMed ID: 26210894
    [TBL] [Abstract][Full Text] [Related]  

  • 16. EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder, the 2011 update.
    Babjuk M; Oosterlinck W; Sylvester R; Kaasinen E; Böhle A; Palou-Redorta J; Rouprêt M;
    Eur Urol; 2011 Jun; 59(6):997-1008. PubMed ID: 21458150
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Comparison of EORTC And CUETO Risk Tables in Terms of the Prediction of Recurrence and Progression in All Non-Muscle-Invasive Bladder Cancer Patients.
    Dalkilic A; Bayar G; Kilinc MF
    Urol J; 2019 Feb; 16(1):37-43. PubMed ID: 30120763
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The EORTC tables overestimate the risk of recurrence and progression in patients with non-muscle-invasive bladder cancer treated with bacillus Calmette-Guérin: external validation of the EORTC risk tables.
    Fernandez-Gomez J; Madero R; Solsona E; Unda M; Martinez-Piñeiro L; Ojea A; Portillo J; Montesinos M; Gonzalez M; Pertusa C; Rodriguez-Molina J; Camacho JE; Rabadan M; Astobieta A; Isorna S; Muntañola P; Gimeno A; Blas M; Martinez-Piñeiro JA;
    Eur Urol; 2011 Sep; 60(3):423-30. PubMed ID: 21621906
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Accuracy of the CUETO, EORTC 2016 and EAU 2021 scoring models and risk stratification tables to predict outcomes in high-grade non-muscle-invasive urothelial bladder cancer.
    Krajewski W; Aumatell J; Subiela JD; Nowak Ł; Tukiendorf A; Moschini M; Basile G; Poletajew S; Małkiewicz B; Del Giudice F; Maggi M; Chung BI; Cimadamore A; Galosi AB; Fave RFD; D'Andrea D; Shariat SF; Hornak J; Babjuk M; Chorbińska J; Teoh JY; Muilwijk T; Joniau S; Tafuri A; Antonelli A; Panunzio A; Alvarez-Maestro M; Simone G; Mastroianni R; Łaszkiewicz J; Lonati C; Zamboni S; Simeone C; Niedziela Ł; Candela L; Macek P; Contieri R; Hidalgo BG; Rivas JG; Sosnowski R; Mori K; Mir C; Soria F; González-Padilla DA; Faba ÒR; Palou J; Ploussard G; Rajwa P; Hałoń A; Laukhtina E; Pradere B; Tully K; Burgos FJ; Cidre MÁJ; Szydełko T;
    Urol Oncol; 2022 Nov; 40(11):491.e11-491.e19. PubMed ID: 35851185
    [TBL] [Abstract][Full Text] [Related]  

  • 20. European Association of Urology (EAU) Prognostic Factor Risk Groups for Non-muscle-invasive Bladder Cancer (NMIBC) Incorporating the WHO 2004/2016 and WHO 1973 Classification Systems for Grade: An Update from the EAU NMIBC Guidelines Panel.
    Sylvester RJ; Rodríguez O; Hernández V; Turturica D; Bauerová L; Bruins HM; Bründl J; van der Kwast TH; Brisuda A; Rubio-Briones J; Seles M; Hentschel AE; Kusuma VRM; Huebner N; Cotte J; Mertens LS; Volanis D; Cussenot O; Subiela Henríquez JD; de la Peña E; Pisano F; Pešl M; van der Heijden AG; Herdegen S; Zlotta AR; Hacek J; Calatrava A; Mannweiler S; Bosschieter J; Ashabere D; Haitel A; Côté JF; El Sheikh S; Lunelli L; Algaba F; Alemany I; Soria F; Runneboom W; Breyer J; Nieuwenhuijzen JA; Llorente C; Molinaro L; Hulsbergen-van de Kaa CA; Evert M; Kiemeney LALM; N'Dow J; Plass K; Čapoun O; Soukup V; Dominguez-Escrig JL; Cohen D; Palou J; Gontero P; Burger M; Zigeuner R; Mostafid AH; Shariat SF; Rouprêt M; Compérat EM; Babjuk M; van Rhijn BWG
    Eur Urol; 2021 Apr; 79(4):480-488. PubMed ID: 33419683
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.